ClinicalTrials.gg
CompletedNCT05861427JPN PIVOTALUpdated Jun 11, 2026Results posted

Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic Migraine

A Phase 3 interventional study of Atogepant and Placebo for Atogepant in Migraine, sponsored by AbbVie. Completed at 48 sites in Japan. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
524
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing atogepant in Migraine Disorders — 6 open to participants now, 7 under way, 4 of them phase 3. atogepant · Migraine Disorders.

Enrollment
10th of 21
524 · median 468
Started
2023
with 2 others
Phase 3
15 of 21
3 open now
Registered
15th of 21
by date
Lead sponsor
11 of 21
AbbVie

Among the 21 studies testing atogepant in Migraine Disorders, this one is the 10th largest by enrollment, is one of 3 that started in 2023, is one of 15 in phase 3, and was the 15th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

6 of the 21 studies testing atogepant in Migraine Disorders are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About atogepant

atogepant: first FDA approval 2021 (QULIPTA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing atogepant in Migraine Disorders, or all of them as a file.
02

Study summary

A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. This study will assess how safe and effective three different doses of atogepant is compared to placebo in adult Japanese participants. Change in migraine symptoms will be assessed.

Atogepant (Qulipta) is an approved drug to treat adults with episodic migraine in the United States. Participants are randomly assigned to one of the 4 treatment groups called Arms to receive atogepant or matching placebo. There is 1 in a 4 chance for the participant to receive placebo. This is double-blinded study which means neither study doctor not the participant will know if the participant received atogepant or placebo. Approximately 520 adult participants with episodic migraine will be enrolled in approximately 50 sites across Japan.

Participants will receive oral atogepant or matching placebo tablets once daily for 12 weeks. At 12 weeks participants assigned to atogepant dose A, dose B or dose C will continue to receive same treatment for 12 additional weeks and participants assigned to placebo will be re-randomized to receive atogepant dose A, dose B or dose C for 12 additional weeks. All participants will be followed for 30 days following last dose of study drug.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The safety and tolerability of the treatment will be checked by medical assessments, blood tests, checking for adverse events and completing questionnaires.

03

Conditions studied

  • Migraine

Browse trials for

Keywords

  • Migraine
  • Episodic Migraine
  • Atogepant
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least a 1-year history of migraine (with or without aura).
  • Less than 50 years of age at the time of migraine onset.
  • History of 4 to 14 migraine days per month in the 3 months prior to screening.
  • 4 to 14 migraine days in the baseline period and completed at least 20 out of 28 days at the baseline period per the eDiary.

Exclusion criteria

Exclusion Criteria:

  • Difficulty with distinguishing migraine headaches from tension-type or other headaches.
  • hematologic, endocrine, pulmonary, renal, hepatic, gastrointestinal, or neurologic disease.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
524 participants (actual)

Study arms

  • Experimental
    Atogepant Dose A

    Participants will receive atogepant dose A once daily (QD) for 24 weeks.

    Drug: Atogepant

  • Experimental
    Atogepant Dose B

    Participants will receive atogepant dose B QD for 24 weeks.

    Drug: Atogepant

  • Experimental
    Atogepant Dose C

    Participants will receive atogepant dose C QD for 24 weeks.

    Drug: Atogepant

  • Experimental
    Placebo

    Participants will receive placebo QD for 12 weeks. Participants will be re-randomized at week 12 to receive atogepant dose A, dose B or dose C QD for 12 weeks.

    Drug: Atogepant · Drug: Placebo for Atogepant

Interventions

  • Oral Tablet

    Also known as: Qulipta

  • DrugPlacebo for Atogepant

    Oral Tablet

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Mean Monthly Migraine Days

    Participants recorded daily duration of migraine in an eDiary. A migraine day was any calendar day on which the participant experienced a migraine headache qualified by duration or acute symptomatic medication use. The monthly (4-week) migraine days was defined as the total number of reported migraine days in eDiary divided by total number of days with eDiary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline was defined as the number of migraine days during the last 28 days of the Baseline phase, from Day -28 to -1. Negative change from Baseline indicates improvement. A Mixed-effects Model for Repeated Measure (MMRM) was used for analysis.

    Time frame: Up to Week 12

  2. Number of Participants Experiencing With Adverse Events (AEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to Week 12

Secondary outcomes

  1. Change From Baseline in Mean Monthly Headache Days

    Participants recorded daily total duration of a headache in an eDiary. A headache day is any calendar day on which the participant experienced a headache qualified by duration or acute symptomatic medication use. The monthly (4-week) headache days were defined as the total number of reported headache days in the eDiary divided by the total number of days with eDiary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline was defined as the number of migraine days during the last 28 days of the Baseline phase, from Day -28 to -1. Negative change from Baseline indicates improvement. MMRM was used for analysis.

    Time frame: Up to Week 12

  2. Change From Baseline in Mean Monthly Acute Medication Use Days

    Participants recorded allowed medication(s) to treat an acute migraine in the daily eDiary. The monthly (4-week) acute medication use days was defined as the total number of reported acute medication use days in the eDiary divided by the total number of days with eDiary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline was defined as the number of acute medication use days during the last 28 days of the Baseline phase, from Day -28 to -1. A negative change from Baseline indicates improvement. MMRM was used for the analysis.

    Time frame: Up to Week 12

  3. Percentage of Participants Achieving At Least 50% Reduction in the 3-month Average of Monthly Migraine Days

    Participants recorded daily duration of migraine in an eDiary. A migraine day was any calendar day on which the participant experienced a migraine headache qualified by duration or acute symptomatic medication use. The monthly (4-week) migraine days is equal to total number of reported migraine days in eDiary divided by total number of days with eDiary records in each 4-week period multiplied by 28. Each 4-week period was averaged.

    Time frame: Up to Week 12

  4. Change From Baseline in Migraine Specific Quality of Life Questionnaire, Version 2.1 (MSQ v2.1) Role Function-Restrictive Domain Score

    MSQ v2.1 is a 14-item questionnaire designed to measure health-related quality-of-life impairments attributed to migraine in the past 4 weeks. It is divided into three domains: role function-restrictive (questions 1-7, score range 7 to 42) assesses how migraines limit one's daily social and work-related activities; role function-preventive (questions 8-11, score ranges 4 to 24) assesses how migraines prevent these activities; and the emotional function (questions 12-14, score ranges 3 to 18) domain assesses the emotions associated with migraines. Participants respond to items using a 6-point scale where 1=none of the time and 6=all of the time. Raw dimension scores are computed as a sum of item responses and rescaled to a 0 to 100 scale, where higher scores from Baseline indicate better quality of life. MMRM was used for the analysis.

    Time frame: Up to Week 12

  5. Change From Baseline in Mean Monthly Performance of Daily Activities Domain Score of the Activity Impairment in Migraine - Diary (AIM-D)

    The AIM-D is an 11-item daily diary measure that assesses the impact of migraine and is comprised of two domains that evaluate performance of daily activities (7 items) and physical impairment (4 items). Participants are asked to rate the level of difficulty experienced in the past 24 hours with performance of daily activities and physical impairment using a 6 point rating scale ranging from "Not difficult at all" to "I could not do it at all." Scores range from 0-100 scale, with higher scores indicating greater impact of migraine.

    Time frame: Up to Week 12

  6. Change From Baseline in Mean Monthly Physical Impairment Domain Score of the AIM-D

    The AIM-D is an 11-item daily diary measure that assesses the impact of migraine and is comprised of two domains that evaluate performance of daily activities (7 items) and physical impairment (4 items). Participants are asked to rate the level of difficulty experienced in the past 24 hours with performance of daily activities and physical impairment using a 6 point rating scale ranging from "Not difficult at all" to "I could not do it at all." Scores range from 0-100 scale, with higher scores indicating greater impact of migraine.

    Time frame: Up to Week 12

07

Results

Posted Jun 11, 2026

Participant flow

Double-Blind Treatment (Wks 1-12)
Participant flow — Double-Blind Treatment (Wks 1-12)
MilestonePlaceboPlacebo/Atogepant 10 mgPlacebo/Atogepant 30 mgPlacebo/Atogepant 60 mgAtogepant 10 mgAtogepant 30 mgAtogepant 60 mg
Started134000127131132
Never received any study treatment0000001
Received randomized study treatment133000126131131
Received study treatment other than randomized1000100
Completed131000124126130
Not completed3000352
Withdrew: Lost to follow-up1000000
Withdrew: Withdrawal by subject1000121
Withdrew: Not disclosed1000231
Active Treatment Extension (Wks 12-24)
Participant flow — Active Treatment Extension (Wks 12-24)
MilestonePlaceboPlacebo/Atogepant 10 mgPlacebo/Atogepant 30 mgPlacebo/Atogepant 60 mgAtogepant 10 mgAtogepant 30 mgAtogepant 60 mg
Started0464342124126130
Completed0454341121125126
Not completed0101314
Withdrew: Lost to follow-up0000001
Withdrew: Withdrawal by subject0100202
Withdrew: Not disclosed0001111

Outcome measures

PrimaryChange From Baseline in Mean Monthly Migraine Days

Participants recorded daily duration of migraine in an eDiary. A migraine day was any calendar day on which the participant experienced a migraine headache qualified by duration or acute symptomatic medication use. The monthly (4-week) migraine days was defined as the total number of reported migraine days in eDiary divided by total number of days with eDiary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline was defined as the number of migraine days during the last 28 days of the Baseline phase, from Day -28 to -1. Negative change from Baseline indicates improvement. A Mixed-effects Model for Repeated Measure (MMRM) was used for analysis.

Time frame:
Up to Week 12
Reported as:
Least squares mean · migraine days per month
Change From Baseline in Mean Monthly Migraine Days
migraine days per monthPlaceboAtogepant 10 mgAtogepant 30 mgAtogepant 60 mg
Change From Baseline in Mean Monthly Migraine Days-1.24 (-1.72 to -0.75)-2.80 (-3.30 to -2.30)-3.14 (-3.63 to -2.64)-3.34 (-3.83 to -2.85)
Statistical analysis
  • Placebo vs Atogepant 10 mg · Mixed-effects Model for Repeated Measure · p = <0.0001 · Ls mean: -1.57 · 95% CI -2.24 to -0.89
  • Placebo vs Atogepant 30 mg · Mixed-effects Model for Repeated Measure · p = <0.0001 · Ls mean: -1.90 · 95% CI -2.57 to -1.22
  • Placebo vs Atogepant 60 mg · Mixed-effects Model for Repeated Measure · p = <0.0001 · Ls mean: -2.10 · 95% CI -2.78 to -1.43
PrimaryNumber of Participants Experiencing With Adverse Events (AEs)

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

Time frame:
Up to Week 12
Reported as:
Count of participants · Participants
Number of Participants Experiencing With Adverse Events (AEs)
ParticipantsPlaceboAtogepant 10 mgAtogepant 30 mgAtogepant 60 mg
Number of Participants Experiencing With Adverse Events (AEs)62575157
SecondaryChange From Baseline in Mean Monthly Headache Days

Participants recorded daily total duration of a headache in an eDiary. A headache day is any calendar day on which the participant experienced a headache qualified by duration or acute symptomatic medication use. The monthly (4-week) headache days were defined as the total number of reported headache days in the eDiary divided by the total number of days with eDiary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline was defined as the number of migraine days during the last 28 days of the Baseline phase, from Day -28 to -1. Negative change from Baseline indicates improvement. MMRM was used for analysis.

Time frame:
Up to Week 12
Reported as:
Least squares mean · headache days per month
Change From Baseline in Mean Monthly Headache Days
headache days per monthPlaceboAtogepant 10 mgAtogepant 30 mgAtogepant 60 mg
Change From Baseline in Mean Monthly Headache Days-1.01 ± 0.269-3.17 ± 0.277-3.31 ± 0.274-3.50 ± 0.275
Statistical analysis
  • Placebo vs Atogepant 10 mg · Mixed-effects Model for Repeated Measure · p = <0.0001 · Ls mean: -2.16 · 95% CI -2.90 to -1.42
  • Placebo vs Atogepant 30 mg · Mixed-effects Model for Repeated Measure · p = <0.0001 · Ls mean: -2.30 · 95% CI -3.04 to -1.57
  • Placebo vs Atogepant 60 mg · Mixed-effects Model for Repeated Measure · p = <0.0001 · Ls mean: -2.49 · 95% CI -3.22 to -1.75
SecondaryChange From Baseline in Mean Monthly Acute Medication Use Days

Participants recorded allowed medication(s) to treat an acute migraine in the daily eDiary. The monthly (4-week) acute medication use days was defined as the total number of reported acute medication use days in the eDiary divided by the total number of days with eDiary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline was defined as the number of acute medication use days during the last 28 days of the Baseline phase, from Day -28 to -1. A negative change from Baseline indicates improvement. MMRM was used for the analysis.

Time frame:
Up to Week 12
Reported as:
Least squares mean · acute medication use days per month
Change From Baseline in Mean Monthly Acute Medication Use Days
acute medication use days per monthPlaceboAtogepant 10 mgAtogepant 30 mgAtogepant 60 mg
Change From Baseline in Mean Monthly Acute Medication Use Days-0.22 ± 0.246-2.34 ± 0.254-2.55 ± 0.250-2.69 ± 0.250
Statistical analysis
  • Placebo vs Atogepant 10 mg · Mixed-effects Model for Repeated Measure · p = <0.0001 · Ls mean: -2.12 · 95% CI -2.80 to -1.44
  • Placebo vs Atogepant 30 mg · Mixed-effects Model for Repeated Measure · p = <0.0001 · Ls mean: -2.33 · 95% CI -3.01 to -1.66
  • Placebo vs Atogepant 60 mg · Mixed-effects Model for Repeated Measure · p = <0.0001 · Ls mean: -2.48 · 95% CI -3.15 to -1.81
SecondaryPercentage of Participants Achieving At Least 50% Reduction in the 3-month Average of Monthly Migraine Days

Participants recorded daily duration of migraine in an eDiary. A migraine day was any calendar day on which the participant experienced a migraine headache qualified by duration or acute symptomatic medication use. The monthly (4-week) migraine days is equal to total number of reported migraine days in eDiary divided by total number of days with eDiary records in each 4-week period multiplied by 28. Each 4-week period was averaged.

Time frame:
Up to Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving At Least 50% Reduction in the 3-month Average of Monthly Migraine Days
percentage of participantsPlaceboAtogepant 10 mgAtogepant 30 mgAtogepant 60 mg
Percentage of Participants Achieving At Least 50% Reduction in the 3-month Average of Monthly Migraine Days15.040.942.350.4
Statistical analysis
  • Placebo vs Atogepant 10 mg · Regression, Logistic · p = <0.0001 · Odds ratio (or): 4.0 · 95% CI 2.19 to 7.20
  • Placebo vs Atogepant 30 mg · Regression, Logistic · p = <0.0001 · Odds ratio (or): 4.2 · 95% CI 2.33 to 7.60
  • Placebo vs Atogepant 60 mg · Regression, Logistic · p = <0.0001 · Odds ratio (or): 5.9 · 95% CI 3.27 to 10.61
SecondaryChange From Baseline in Migraine Specific Quality of Life Questionnaire, Version 2.1 (MSQ v2.1) Role Function-Restrictive Domain Score

MSQ v2.1 is a 14-item questionnaire designed to measure health-related quality-of-life impairments attributed to migraine in the past 4 weeks. It is divided into three domains: role function-restrictive (questions 1-7, score range 7 to 42) assesses how migraines limit one's daily social and work-related activities; role function-preventive (questions 8-11, score ranges 4 to 24) assesses how migraines prevent these activities; and the emotional function (questions 12-14, score ranges 3 to 18) domain assesses the emotions associated with migraines. Participants respond to items using a 6-point scale where 1=none of the time and 6=all of the time. Raw dimension scores are computed as a sum of item responses and rescaled to a 0 to 100 scale, where higher scores from Baseline indicate better quality of life. MMRM was used for the analysis.

Time frame:
Up to Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in Migraine Specific Quality of Life Questionnaire, Version 2.1 (MSQ v2.1) Role Function-Restrictive Domain Score
score on a scalePlaceboAtogepant 10 mgAtogepant 30 mgAtogepant 60 mg
Change From Baseline in Migraine Specific Quality of Life Questionnaire, Version 2.1 (MSQ v2.1) Role Function-Restrictive Domain Score8.33 ± 1.22915.39 ± 1.26517.19 ± 1.25017.55 ± 1.245
Statistical analysis
  • Placebo vs Atogepant 10 mg · Mixed-effects Model for Repeated Measure · p = 0.0001 · Ls mean: 7.06 · 95% CI 3.65 to 10.47
  • Placebo vs Atogepant 30 mg · Mixed-effects Model for Repeated Measure · p = <0.0001 · Ls mean: 8.86 · 95% CI 5.47 to 12.25
  • Placebo vs Atogepant 60 mg · Mixed-effects Model for Repeated Measure · p = <0.0001 · Ls mean: 9.23 · 95% CI 5.86 to 12.60
SecondaryChange From Baseline in Mean Monthly Performance of Daily Activities Domain Score of the Activity Impairment in Migraine - Diary (AIM-D)

The AIM-D is an 11-item daily diary measure that assesses the impact of migraine and is comprised of two domains that evaluate performance of daily activities (7 items) and physical impairment (4 items). Participants are asked to rate the level of difficulty experienced in the past 24 hours with performance of daily activities and physical impairment using a 6 point rating scale ranging from "Not difficult at all" to "I could not do it at all." Scores range from 0-100 scale, with higher scores indicating greater impact of migraine.

Time frame:
Up to Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in Mean Monthly Performance of Daily Activities Domain Score of the Activity Impairment in Migraine - Diary (AIM-D)
score on a scalePlaceboAtogepant 10 mgAtogepant 30 mgAtogepant 60 mg
Change From Baseline in Mean Monthly Performance of Daily Activities Domain Score of the Activity Impairment in Migraine - Diary (AIM-D)-2.35 ± 0.357-4.73 ± 0.369-5.31 ± 0.364-4.90 ± 0.367
Statistical analysis
  • Placebo vs Atogepant 10 mg · Mixed-effects Model for Repeated Measure · p = <0.0001 · Ls mean: -2.39 · 95% CI -3.37 to -1.40
  • Placebo vs Atogepant 30 mg · Mixed-effects Model for Repeated Measure · p = <0.0001 · Ls mean: -2.96 · 95% CI -3.94 to -1.98
  • Placebo vs Atogepant 60 mg · Mixed-effects Model for Repeated Measure · p = <0.0001 · Ls mean: -2.55 · 95% CI -3.53 to -1.57
SecondaryChange From Baseline in Mean Monthly Physical Impairment Domain Score of the AIM-D

The AIM-D is an 11-item daily diary measure that assesses the impact of migraine and is comprised of two domains that evaluate performance of daily activities (7 items) and physical impairment (4 items). Participants are asked to rate the level of difficulty experienced in the past 24 hours with performance of daily activities and physical impairment using a 6 point rating scale ranging from "Not difficult at all" to "I could not do it at all." Scores range from 0-100 scale, with higher scores indicating greater impact of migraine.

Time frame:
Up to Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in Mean Monthly Physical Impairment Domain Score of the AIM-D
score on a scalePlaceboAtogepant 10 mgAtogepant 30 mgAtogepant 60 mg
Change From Baseline in Mean Monthly Physical Impairment Domain Score of the AIM-D-2.12 ± 0.351-4.32 ± 0.363-4.89 ± 0.357-4.49 ± 0.360
Statistical analysis
  • Placebo vs Atogepant 10 mg · Mixed-effects Model for Repeated Measure · p = <0.0001 · Ls mean: -2.20 · 95% CI -3.17 to -1.23
  • Placebo vs Atogepant 30 mg · Mixed-effects Model for Repeated Measure · p = <0.0001 · Ls mean: -2.77 · 95% CI -3.73 to -1.81
  • Placebo vs Atogepant 60 mg · Mixed-effects Model for Repeated Measure · p = <0.0001 · Ls mean: -2.37 · 95% CI -3.33 to -1.41

Adverse events

Collected over All-cause mortality & AE tables include events reported from time of informed consent to end of study. Median time on follow-up was 200, 200.5, 200, 200, 200, 201 & 200 days for Pbo, Pbo/10mg, Pbo/30mg, Pbo/60mg, Atogepant 10mg, 30mg & 60mg, respectively. One subject randomized to 60mg never recd study treatment (included in ITT 60mg but not in SP1); one subject randomized to 10mg took 60mg; one subject randomized to placebo then re-randomized to 60mg at Wk 12 recd 30mg from Wk 12-24.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/134 (0%)1/134 (0.7%)38/134 (28.4%)
Placebo/Atogepant 10 mg0/46 (0%)1/46 (2.2%)18/46 (39.1%)
Placebo/Atogepant 30 mg0/43 (0%)0/44 (0%)15/44 (34.1%)
Placebo/Atogepant 60 mg0/42 (0%)0/41 (0%)12/41 (29.3%)
Atogepant 10 mg0/127 (0%)2/126 (1.6%)39/126 (31%)
Atogepant 30 mg0/131 (0%)1/131 (0.8%)40/131 (30.5%)
Atogepant 60 mg0/132 (0%)0/132 (0%)40/132 (30.3%)
Most frequent serious events
Most frequent serious events
EventPlaceboPlacebo/Atogepant 10 mgPlacebo/Atogepant 30 mgPlacebo/Atogepant 60 mgAtogepant 10 mgAtogepant 30 mgAtogepant 60 mg
HAEMORRHOIDSGastrointestinal disorders1/1341/460/440/410/1260/1310/132
PRINZMETAL ANGINACardiac disorders0/1340/460/440/411/1260/1310/132
OROPHARYNGEAL CANCERNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1340/460/440/411/1260/1310/132
ANAEMIABlood and lymphatic system disorders0/1340/460/440/410/1261/1310/132
Most frequent other events
Most frequent other events
EventPlaceboPlacebo/Atogepant 10 mgPlacebo/Atogepant 30 mgPlacebo/Atogepant 60 mgAtogepant 10 mgAtogepant 30 mgAtogepant 60 mg
NASOPHARYNGITISInfections and infestations27/1347/4611/449/4121/12623/13119/132
CONSTIPATIONGastrointestinal disorders12/1347/462/443/416/12613/13115/132
COVID-19Infections and infestations5/1342/463/440/419/1264/1317/132
ABDOMINAL PAIN UPPERGastrointestinal disorders0/1343/460/441/413/1265/1315/132
PYREXIAGeneral disorders0/1342/461/441/414/1260/1312/132
GASTRITISGastrointestinal disorders0/1341/460/441/411/1261/1311/132
VAGINAL HAEMORRHAGEReproductive system and breast disorders0/1340/460/440/410/1260/1310/132

Baseline characteristics

Safety Population 1; One participant was randomized but never received any study treatment.

Age, Continuous
Age, Continuous(years)PlaceboAtogepant 10 mgAtogepant 30 mgAtogepant 60 mgTotal
Mean44.8 ± 10.5441.3 ± 11.7143.2 ± 11.4042.5 ± 10.2543.0 ± 11.02
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAtogepant 10 mgAtogepant 30 mgAtogepant 60 mgTotal
Female117106104110437
Male1720272286
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboAtogepant 10 mgAtogepant 30 mgAtogepant 60 mgTotal
Hispanic or Latino00000
Not Hispanic or Latino134126131132523
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboAtogepant 10 mgAtogepant 30 mgAtogepant 60 mgTotal
American Indian or Alaska Native00000
Asian134126131132523
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White00000
More than one race00000
Unknown or Not Reported00000
08

Study locations

48 sites
  • Tokyo Dental College Ichikawa General Hospital /ID# 247436
    Ichikawa-shi, Chiba 272-0824, Japan
  • Takanoko Hospital /ID# 245658
    Matsuyama, Ehime 790-0925, Japan
  • Fukuiken Saiseikai Hospital /ID# 245662
    Fukui-shi, Fukui 918-8503, Japan
  • Jinnouchi Neurosurgical Clinic /ID# 245510
    Kasuga-shi, Fukuoka 816-0802, Japan
  • Ikeda Neurosurgical Clinic /ID# 245881
    Kasuga-shi, Fukuoka 816-0824, Japan
  • SUBARU Health Insurance Society Ota Memorial Hospital /ID# 247948
    Ota-shi, Gunma 373-8585, Japan
  • Hiroshima City Hiroshima Citizens Hospital /ID# 246683
    Hiroshima, Hiroshima 730-8518, Japan
  • Higashi Sapporo Neurology And Neurosurgery Clinic /ID# 245667
    Sapporo, Hokkaido 003-0003, Japan
  • Nakamura Memorial Hospital /ID# 247379
    Sapporo, Hokkaido 060-8570, Japan
  • Konan Medical Center /ID# 245557
    Kobe, Hyōgo 658-0064, Japan
  • Nishinomiya Municipal Central Hospital /ID# 246571
    Nishinomiya-shi, Hyōgo 663-8014, Japan
  • Yamaguchi Clinic /ID# 246370
    Nishinomiya-shi, Hyōgo 663-8204, Japan
  • Mito Kyodo General Hospital /ID# 245487
    Mito, Ibaraki 310-0015, Japan
  • Tsukuba Neurosurgery/Headache Clinic /ID# 254665
    Tsukuba, Ibaraki 305-0822, Japan
  • Kijima Neurosurgery Clinic /ID# 245758
    Kahoku-gun, Ishikawa-ken 929-0342, Japan
  • Kanazawa Neurosurgical Hospital /ID# 254210
    Nonoichi-shi, Ishikawa-ken 921-8841, Japan
  • Kokubu Clinic /ID# 245810
    Takamatsu, Kagawa-ken 769-0103, Japan
  • Tokai University Hospital /ID# 245971
    Isehara, Kanagawa 259-1193, Japan
  • Fujitsu Clinic /ID# 245811
    Kawasaki-shi, Kanagawa 211-8588, Japan
  • Atago Hospital /ID# 245818
    Kochi, Kochi 780-0051, Japan
  • Umenotsuji Clinic /ID# 246103
    Kochi, Kochi 780-8011, Japan
  • Saiseikai Kumamoto Hospital /Id# 253546
    Kumamoto, Kumamoto 861-4101, Japan
  • Narikawa Neurological Clinic /ID# 254023
    Sendai, Miyagi 981-3126, Japan
  • Sendai Headache and Neurology Clinic Medical Corporation /ID# 245664
    Sendai, Miyagi 982-0014, Japan
  • Ooba Clinic for Neurosurgery & Headache /ID# 246201
    Ōita, Oita Prefecture 8700831, Japan
  • Makabe Clinic /ID# 246621
    Okayama, Okayama-ken 700-0964, Japan
  • Okayama City General Medical Center /ID# 246007
    Okayama, Okayama-ken 700-8557, Japan
  • Gokeikai Osaka Kaisei Hospital /ID# 246623
    Osaka, Osaka 532-0003, Japan
  • Chibune General Hospital /ID# 245973
    Osaka, Osaka 555-0034, Japan
  • Tominaga Clinic /ID# 245812
    Osaka, Osaka 5560015, Japan
  • Takase Internal Medicine Clinic /ID# 245532
    Toyonaka-shi, Osaka 560-0012, Japan
  • Saitama Medical University Hospital /ID# 245663
    Iruma-gun, Saitama 350-0495, Japan
  • Saino Clinic /ID# 245921
    Tokorozawa-shi, Saitama 359-1141, Japan
  • Japanese Red Cross Shizuoka Hospital /ID# 246204
    Shizuoka, Shizuoka 420-0853, Japan
  • Dokkyo Medical University Hospital /ID# 246472
    Mibu, Tochigi 321-0293, Japan
  • Tokai University Hachioji Hospital /ID# 248326
    Hachioji-shi, Tokyo 192-0032, Japan
  • Kitasato University Kitasato Institute Hospital /ID# 246470
    Minato-ku, Tokyo 108-8642, Japan
  • Usuda Clinic Of Internal Medicine /ID# 246166
    Setagaya-ku, Tokyo 156-0043, Japan
  • Tokyo Headache Clinic /ID# 245486
    Shibuya-ku, Tokyo 151-0051, Japan
  • Keio University Hospital /ID# 245660
    Shinjuku-ku, Tokyo 160-8582, Japan
  • Suzuki Kei Yasuragi Clinic /ID# 253493
    Tachikawa-shi, Tokyo 190-0001, Japan
  • Sakura neuro Clinic /ID# 248320
    Toyama, Toyama 930-0803, Japan
  • Tendo Brain Clinic /ID# 246205
    Tendo-shi, Yamagata 994-0083, Japan
  • Nagaseki Headache Clinic /ID# 245485
    Kai, Yamanashi 400-0124, Japan
  • DOI Internal Medicine-Neurology Clinic /ID# 245661
    Hiroshima, 730-0031, Japan
  • Tanaka Neurosurgery & Headache Clinic /ID# 245488
    Kagoshima, 890-0052, Japan
  • Tatsuoka Neurology Clinic /ID# 245328
    Kyoto, 600-8811, Japan
  • Shinagawa Strings Clinic /ID# 245665
    Tokyo, 108-0075, Japan
09

References and documents

Publications

  • Matsumori Y, Yamada H, Nagaseki Y, Shimizu K, Nagy K, Matsuzawa R, Otani T, He MY, Guo H, Ahmadyar G, Takeshima T. Atogepant for the preventive treatment of episodic migraine in Japanese participants: A phase 2/3, randomized, double-blind, placebo-controlled trial with an active treatment extension (RELEASE). Cephalalgia. 2025 Sep;45(9):3331024251374569. doi: 10.1177/03331024251374569. Epub 2025 Sep 26. PubMed 41002192 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Mar 2025, 19 months.

Results were first posted in Jun 2026, 1 year 3 months after primary completion.

Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 19 months is close to that.

Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2023
First posted
May 16, 2023
StartActual
Jul 12, 2023
Primary completionActual
Mar 1, 2025
CompletionActual
Mar 1, 2025
Results first posted
Jun 11, 2026
Last update
Jun 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05861427
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
May 16, 2023
Start date
Jul 12, 2023
Primary completion
Mar 1, 2025
Completion
Mar 1, 2025
Results posted
Jun 11, 2026
Last update
Jun 11, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atogepant

Start the discussion